We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics


DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App

DiaSorin Receives BARDA Funding to Develop Rapid COVID-19 Test

By LabMedica International staff writers
Posted on 27 Mar 2020
Print article
Image: The LIAISON MDX platform (Photo courtesy of DiaSorin Inc.)
Image: The LIAISON MDX platform (Photo courtesy of DiaSorin Inc.)
DiaSorin Molecular LLC, a wholly-owned subsidiary of DiaSorin Inc. (‎Saluggia‎, Italy), has received Emergency Use Authorization (EUA) from the FDA for its Simplexa COVID-19 Direct kit. The kit provides a sample-to-answer test for the detection of severe acute respiratory syndrome coronavirus (SARS-CoV-2), the virus that causes COVID-19, directly from nasopharyngeal swab specimens.

DiaSorin Molecular LLC manufactures and distributes molecular diagnostic products for hospital and reference laboratories. The company’s products help laboratories consolidate their testing, streamline processes and increase efficiency. DiaSorin Molecular’s Simplexa molecular diagnostic kits are designed for use on the company’s versatile LIAISON MDX platform. The company also markets a range of ASRs (analyte-specific reagents) for use in lab-developed tests.

The Simplexa COVID-19 Direct kit is also designed for use on the LIAISON MDX. It can be utilized by hospital laboratories without the need to send the sample out, allowing for timely testing and results. The kit contains an all-in-one reagent mix which is ready to use. Only one instrument and one reagent are required to perform the test. It bypasses the need for traditional extraction procedures, enabling rapid detection in a little over an hour which is significantly faster than the time of up to seven hours currently required by traditional extraction, followed by amplification technologies, ultimately allowing prompt decision-making on isolating infected patients. The test is highly specific to COVID-19 and targets several regions of the viral genome to minimize the impact on performance, should there be possible future mutations. This ensures that the results are highly sensitive and specific, providing confidence in diagnostic decision making.

DiaSorin Molecular has received federal funds from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, in order to develop the test. Given the need to increase the testing capacity at hospitals across the US, the funding is expected to accelerate the availability of diagnostic testing in order to help mitigate the potential impact of this virus.

“We are excited for the launch of our COVID-19 test and hope to help reduce the current shortage of tests being experienced by hospitals worldwide,” said John Gerace, president of DiaSorin Molecular. “This test will better enable clinicians to make appropriate diagnostic decisions by providing rapid and accurate results. We know it will play a critical role in containing the pandemic.”

Related Links:
DiaSorin Inc.

Print article


Molecular Diagnostics

view channel
Image: Pre-eclampsia: high magnification micrograph of hypertrophic decidual vasculopathy, as seen in pregnancy-induced hypertension. (Photo courtesy of Wikimedia Commons)

Serum MicroRNAs Predict Likelihood of Pregnant Women Developing Pre-Eclampsia

MicroRNA biomarkers have been identified in the blood of asymptomatic pregnant women that can be used to predict the potential onset of pre-eclampsia. Pre-eclampsia (PE) is a disorder of pregnancy characterized... Read more


view channel
Image: Stenotrophomonas maltophilia colonies on sheep blood agar. Cultivation 48 hours in an aerobic atmosphere, 37 °C (Photo courtesy of microbiologyinpictures).

Global Spread of the Multi-Resistant Pathogen Stenotrophomonas Maltophilia Revealed

Stenotrophomonas maltophilia strains occur in several natural and human associated ecosystems. The bacterium was long regarded as relatively unproblematic, but is now considered to be one of the most feared... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.